CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
Fispemifene once daily for 4 weeksdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00290134
NCT00290134Phase 2Completed
CompareCT.gov

Preliminary Efficacy and Safety of Fispemifene in the Treatment of Hypogonadism: A 4 Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Daily Oral Doses of 100, 200, and 300 mg Fispemifene and Placebo

QuatRx Pharmaceuticals Company·interventional·Posted Feb 10, 2006·Updated Mar 3, 2008

In Brief

A Phase 2 clinical trial evaluating Fispemifene once daily for 4 weeks for Hypogonadism. Completed, across 16 sites.

Detailed Summary

The purpose of this study is to determine whether one or more fispemifene dose regimens are more effective than placebo in the treatment of hypogonadism in older men.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypogonadism
CountriesUnited States
CollaboratorsHormos Medical

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 10, 2006
Enrollment StartFeb 1, 2006
Study CompletionOct 1, 2007
TodayJul 2, 2026
Posted 20.4 years ago

Interventions

Fispemifene once daily for 4 weeksdrug